{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:17:38Z","timestamp":1783160258214,"version":"3.54.6"},"update-to":[{"DOI":"10.1016\/j.clinbiochem.2025.110980","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clinbiochem.2025.111015","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:44:25Z","timestamp":1759146265000},"page":"111015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The biological diagnosis of Alzheimer\u2019s disease using blood-based biomarkers: a Canadian prospective"],"prefix":"10.1016","volume":"140","author":[{"given":"Pankaj","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Frykman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2025.111015_b0005","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer\u2019s disease facts and figures, Alzheimer\u2019s Dement. 20(5) (2024) 3708\u20133821. https:\/\/doi.org\/10.1002\/alz.13809.","DOI":"10.1002\/alz.13809"},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneurol.2017.63","article-title":"The changing prevalence and incidence of dementia over time \u2014 current evidence","volume":"13","author":"Wu","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0015","unstructured":"World Health Organization, Dementia, WHO."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0020","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer\u2019s disease facts and figures, Alzheimer\u2019s Dement. 19(4) (2023) 1598\u20131695. https:\/\/doi.org\/10.1002\/alz.13016.","DOI":"10.1002\/alz.13016"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12963-016-0107-z","article-title":"Alzheimer\u2019s and other dementias in Canada, 2011 to 2031: a microsimulation Population Health Modeling (POHEM) study of projected prevalence, health burden, health services, and caregiving use","volume":"14","author":"Manuel","year":"2016","journal-title":"Popul. Health Metr."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0030","unstructured":"Economic Burden of Dementia in Canada, Canadian Centre for Economic Analysis, 2023."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.111015_b0035","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00401-015-1406-3","article-title":"Neuropathologically mixed Alzheimer\u2019s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes","volume":"129","author":"Walker","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"22","key":"10.1016\/j.clinbiochem.2025.111015_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214498","article-title":"Protein misfolding and aggregation in the brain: common pathogenetic pathways in neurodegenerative and mental disorders","volume":"23","author":"Ochneva","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrneurol.2017.162","article-title":"Amyloid-\u03b2 and tau complexity \u2014 towards improved biomarkers and targeted therapies","volume":"14","author":"Polanco","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/jon.13001","article-title":"The tauopathies: neuroimaging characteristics and emerging experimental therapies","volume":"32","author":"Riley","year":"2022","journal-title":"J. Neuroimaging"},{"issue":"13","key":"10.1016\/j.clinbiochem.2025.111015_b0060","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.111015_b0065","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13195-023-01314-6","article-title":"Biomarkers in Alzheimer\u2019s disease: role in early and differential diagnosis and recognition of atypical variants","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimers Res. Ther."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0075","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","article-title":"Cerebrospinal fluid tau\/\u03b2-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"Fagan","year":"2007","journal-title":"Arch. Neurol."},{"issue":"22","key":"10.1016\/j.clinbiochem.2025.111015_b0090","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-021-00234-5","article-title":"Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"10","author":"Ding","year":"2021","journal-title":"Transl. Neurodegener."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0105","first-page":"1","article-title":"Plasma biomarkers of ad emerging as essential tools for drug development: an EU\/US CTAD task force report","author":"Bateman","year":"2019","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.111015_b0110","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0115","unstructured":"Amyloid, the presenilins and Alzheimer\u2019s disease."},{"issue":"5580","key":"10.1016\/j.clinbiochem.2025.111015_b0120","first-page":"353","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science (1979)"},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0125","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.111015_b0130","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-0082(03)00089-3","article-title":"Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory","volume":"70","author":"Turner","year":"2003","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00401-016-1606-5","article-title":"Vascular, glial, and lymphatic immune gateways of the central nervous system","volume":"132","author":"Engelhardt","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.111015_b0150","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.jmb.2017.03.018","article-title":"Interactions between tau and different conformations of tubulin: implications for tau function and mechanism","volume":"429","author":"Duan","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00003","article-title":"The metamorphic nature of the tau protein: dynamic flexibility comes at a cost","volume":"10","author":"Sabbagh","year":"2016","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-015-0025-8","article-title":"Regulation of human MAPT gene expression","volume":"10","author":"Caillet-Boudin","year":"2015","journal-title":"Mol. Neurodegener."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0165","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neuint.2010.12.023","article-title":"Post-translational modifications of tau protein: Implications for Alzheimer\u2019s disease","volume":"58","author":"Martin","year":"2011","journal-title":"Neurochem. Int."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","article-title":"Propagation of tau aggregates and neurodegeneration","volume":"40","author":"Goedert","year":"2017","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0175","doi-asserted-by":"crossref","unstructured":"A. Himmler, D. Drechsel, M.W. Kirschner, D.W. Martin, Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. 9 (1989).","DOI":"10.1128\/mcb.9.4.1381-1388.1989"},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111015_b0180","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0185","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2013.00112","article-title":"Hyperphosphorylation-induced tau oligomers","volume":"4","author":"Iqbal","year":"2013","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0195","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1038\/s41467-022-30461-x","article-title":"Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses","volume":"13","author":"Meng","year":"2022","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.clinbiochem.2025.111015_b0200","doi-asserted-by":"crossref","first-page":"9207","DOI":"10.3390\/ijms22179207","article-title":"Tau protein interaction partners and their roles in Alzheimer\u2019s disease and other tauopathies","volume":"22","author":"Sinsky","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.clinbiochem.2025.111015_b0205","doi-asserted-by":"crossref","first-page":"12841","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0210","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1046\/j.1471-4159.2000.0741587.x","article-title":"Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry","volume":"74","author":"Reynolds","year":"2000","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b0215","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1074\/jbc.270.2.823","article-title":"Proline-directed and non-proline-directed phosphorylation of PHF-tau","volume":"270","author":"Morishima-Kawashima","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0220","first-page":"11","article-title":"Tau Post-translational modifications: dynamic transformers of tau function, degradation, and aggregation","author":"Alquezar","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0225","first-page":"15","article-title":"Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies","author":"Yuan","year":"2021","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.111015_b0230","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1515\/cclm-2023-0036","article-title":"Neurofilament light chain as neuronal injury marker \u2013 what is needed to facilitate implementation in clinical laboratory practice?","volume":"61","author":"Arslan","year":"2023","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0235","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0240","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pneurobio.2011.01.005","article-title":"GFAP in health and disease","volume":"93","author":"Middeldorp","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0245","article-title":"Glial fibrillary acidic protein in blood as a disease biomarker of neuromyelitis optica spectrum disorders","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0250","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1212\/01.WNL.0000080366.90234.7F","article-title":"Mild cognitive impairment","volume":"61","author":"Luis","year":"2003","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.111015_b0255","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1212\/01.WNL.0000034176.07159.F8","article-title":"Incidence and outcome of mild cognitive impairment in a population-based prospective cohort","volume":"59","author":"Larrieu","year":"2002","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0260","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1212\/01.WNL.0000132523.27540.81","article-title":"Mild cognitive impairment, amnestic type","volume":"63","author":"Ganguli","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2025.111015_b0265","first-page":"123","article-title":"Alzheimer\u2019s disease \u2013 why we need early diagnosis","volume":"9","author":"Rasmussen","year":"2019","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0270","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer\u2019s disease in the era of biomarkers","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.111015_b0275","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","article-title":"Practice parameter: diagnosis of dementia (an evidence-based review)","volume":"56","author":"Knopman","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0280","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at national institute on aging Alzheimer Disease Centers, 2005\u20132010","volume":"71","author":"Beach","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.111015_b0285","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0290","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0295","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.111015_b0300","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.111015_b0305","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MNM.0b013e3281e20a12","article-title":"Imaging in dementia with Lewy bodies: a review","volume":"28","author":"Kemp","year":"2007","journal-title":"Nucl. Med. Commun."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.111015_b0310","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1468-1331.2012.03859.x","article-title":"EFNS task force: the use of neuroimaging in the diagnosis of dementia","volume":"19","author":"Filippi","year":"2012","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-018-8892-x","article-title":"Neuroimaging in Lewy body dementia","volume":"266","author":"Yousaf","year":"2019","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.111015_b0320","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0325","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2010Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0330","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA\u2010AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111015_b0335","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0340","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Intervent."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0345","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Intervent."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.111015_b0350","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209884","article-title":"Challenges in a biological definition of Alzheimer disease","volume":"103","author":"Hazan","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0355","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","article-title":"Biomarker modeling of Alzheimer\u2019s disease","volume":"80","author":"Jack","year":"2013","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0360","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimer\u2019s Dement."},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.111015_b0370","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1093\/brain\/awz268","article-title":"The bivariate distribution of amyloid-\u03b2 and tau: relationship with established neurocognitive clinical syndromes","volume":"142","author":"Jack","year":"2019","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.111015_b0375","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaneurol.2023.2560","article-title":"Increased medial temporal tau positron emission tomography uptake in the absence of amyloid-\u03b2 positivity","volume":"80","author":"Costoya-S\u00e1nchez","year":"2023","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b0380","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrneurol.2015.251","article-title":"Suspected non-Alzheimer disease pathophysiology \u2014 concept and controversy","volume":"12","author":"Jack","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0385","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0390","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201389","article-title":"Impact of amyloid and tau PET on changes in diagnosis and patient management","volume":"100","author":"Shimohama","year":"2023","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0395","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/alz.12875","article-title":"Tau\u2010PET is superior to phospho\u2010tau when predicting cognitive decline in symptomatic AD patients","volume":"19","author":"Smith","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111015_b0400","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111015_b0405","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaneurol.2024.1612","article-title":"Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairment","volume":"81","author":"Groot","year":"2024","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b0410","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac017","article-title":"Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk","volume":"4","author":"Jack","year":"2022","journal-title":"Brain Commun."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b0415","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"issue":"Supplement 1","key":"10.1016\/j.clinbiochem.2025.111015_b0420","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.2967\/jnumed.121.263196","article-title":"Tau PET imaging in neurodegenerative disorders","volume":"63","author":"Groot","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0425","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer\u2019s disease dementia","volume":"142","author":"Pontecorvo","year":"2019","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b0430","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00259-019-04496-0","article-title":"Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948","volume":"47","author":"Smith","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.111015_b0435","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00259-021-05401-4","article-title":"A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis","volume":"48","author":"Leuzy","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0440","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mds.26834","article-title":"18[F]AV\u20101451 tau positron emission tomography in progressive supranuclear palsy","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111015_b0445","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1212\/WNL.0000000000004264","article-title":"In vivo retention of 18 F-AV-1451 in corticobasal syndrome","volume":"89","author":"Smith","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.111015_b0450","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.111015_b0455","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/alz.12356","article-title":"Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer\u2019s disease","volume":"17","author":"Ossenkoppele","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.111015_b0460","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000100926","article-title":"Prediction of Alzheimer\u2019s disease using the CSF A\u03b242\/A\u03b240 ratio in patients with mild cognitive impairment","volume":"23","author":"Hansson","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0465","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0197-4580(03)00086-1","article-title":"Neurochemical diagnosis of Alzheimer\u2019s dementia by CSF A\u03b242, A\u03b242\/A\u03b240 ratio and total tau","volume":"25","author":"Lewczuk","year":"2004","journal-title":"Neurobiol. Aging"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0470","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","article-title":"Amyloid \u03b2 peptide ratio 42\/40 but not A\u03b242 correlates with phospho\u2010Tau in patients with low\u2010 and high\u2010CSF A\u03b240 load","volume":"101","author":"Wiltfang","year":"2007","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0475","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.111015_b0480","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/alz.12897","article-title":"Robustness of CSF A\u03b242\/40 and A\u03b242\/P\u2010tau181 measured using fully automated immunoassays to detect AD\u2010related outcomes","volume":"19","author":"Leuzy","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.111015_b0485","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid \u03b2-amyloid 42","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0490","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF a \u03b2 42\/A \u03b2 40 and a \u03b2 42\/A \u03b2 38 ratios: better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0495","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JAD-150247","article-title":"Alzheimer\u2019s disease normative cerebrospinal fluid biomarkers validated in PET amyloid-\u03b2 characterized subjects from the Australian imaging, biomarkers and lifestyle (AIBL) study","volume":"48","author":"Li","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0500","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.24125","article-title":"Mild to moderate Alzheimer dementia with insufficient neuropathological changes","volume":"75","author":"Serrano-Pozo","year":"2014","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0505","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2010Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111015_b0510","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS\u2013ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b0515","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JAD-132489","article-title":"Qualification of a surrogate matrix-based absolute quantification method for amyloid-\u03b242 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry","volume":"41","author":"Korecka","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"22","key":"10.1016\/j.clinbiochem.2025.111015_b0520","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","article-title":"A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking","volume":"73","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0525","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0530","series-title":"In","first-page":"27","article-title":"Guidelines for CSF processing and biobanking: impact on the identification and development of optimal CSF protein biomarkers","author":"Hok-A-Hin","year":"2019"},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.111015_b0535","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer\u2019s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.111015_b0540","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1515\/cclm-2018-0147","article-title":"Commutability of the certified reference materials for the standardization of \u03b2-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and \u03b2-amyloid 1-40 measurements","volume":"56","author":"Andreasson","year":"2018","journal-title":"Clin. Chem. Lab. Med. (CCLM)."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.111015_b0545","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00259-021-05258-7","article-title":"2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"48","author":"Leuzy","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.111015_b0550","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","article-title":"Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of \u03b2\u2010amyloid (1\u201342) in human cerebrospinal fluid","volume":"12","author":"Bittner","year":"2016","journal-title":"Alzheimer\u2019s Dement."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0555","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3233\/JAD-170773","article-title":"The past and the future of Alzheimer\u2019s disease fluid biomarkers","volume":"62","author":"Blennow","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.111015_b0560","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","article-title":"Mass spectrometry\u2013based candidate reference measurement procedure for quantification of amyloid-\u03b2 in cerebrospinal fluid","volume":"60","author":"Leinenbach","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0565","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clinbiochem.2019.05.005","article-title":"Elecsys\u00ae total-tau and phospho-tau (181P) CSF assays: analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid","volume":"72","author":"Lifke","year":"2019","journal-title":"Clin. Biochem."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0570","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/JAD-160298","article-title":"Performance evaluation of an automated ELISA system for Alzheimer\u2019s disease detection in clinical routine","volume":"54","author":"Chiasserini","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0575","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","article-title":"Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease","volume":"11","author":"Leit\u00e3o","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.111015_b0580","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00415-019-09418-6","article-title":"Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid A\u03b242 and T-Tau assays for Alzheimer\u2019s disease diagnosis","volume":"266","author":"Bayart","year":"2019","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.111015_b0585","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/alz.12145","article-title":"First amyloid \u03b21\u201042 certified reference material for re\u2010calibrating commercial immunoassays","volume":"16","author":"Boulo","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"issue":"18","key":"10.1016\/j.clinbiochem.2025.111015_b0590","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0840","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0630","article-title":"Clinical decision points for two plasma p\u2010tau217 laboratory developed tests in neuropathology confirmed samples","volume":"17","author":"Mammel","year":"2025","journal-title":"Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monitor."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0845","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GIM.0b013e318184137c","article-title":"The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP Working Group","volume":"11","author":"Teutsch","year":"2009","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0850","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1373\/clinchem.2017.281808","article-title":"The biological variation data critical appraisal checklist: a standard for evaluating studies on biological variation","volume":"64","author":"Aarsand","year":"2018","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b0855","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/alz.13518","article-title":"Biological variation estimates of Alzheimer\u2019s disease plasma biomarkers in healthy individuals","volume":"20","author":"Brum","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0835","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70038","article-title":"Diagnostic accuracy of plasma p\u2010tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0860","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2014-1127","article-title":"A checklist for critical appraisal of studies of biological variation","volume":"53","author":"Bartlett","year":"2015","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0865","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1258\/acb.2009.009006","article-title":"Reference change values: the way forward in monitoring","volume":"46","author":"Fraser","year":"2009","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b0870","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/clinchem\/hvaa233","article-title":"Personalized reference intervals in laboratory medicine: a new model based on within-subject biological variation","volume":"67","author":"Co\u015fkun","year":"2021","journal-title":"Clin. Chem."},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.111015_b0875","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1515\/cclm-2016-0035","article-title":"Sample collections from healthy volunteers for biological variation estimates\u2019 update: a new project undertaken by the Working Group on Biological Variation established by the European Federation of Clinical Chemistry and Laboratory Medicine","volume":"54","author":"Carobene","year":"2016","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0880","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1515\/cclm-2021-0370","article-title":"The European Biological Variation Study (EuBIVAS): a summary report","volume":"60","author":"Carobene","year":"2022","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111015_b0885","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1515\/cclm-2024-0108","article-title":"Analytical performance specifications based on biological variation data \u2013 considerations, strengths and limitations","volume":"62","author":"Sandberg","year":"2024","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.111015_b0890","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: Head\u2010to\u2010head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0895","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.111015_b0900","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head\u2010to\u2010head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0905","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers","volume":"80","author":"Mattsson-Carlgren","year":"2023","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0910","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-022-01005-8","article-title":"Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217","volume":"14","author":"Groot","year":"2022","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0635","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-51334-x","article-title":"Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer\u2019s disease","volume":"14","author":"Kivis\u00e4kk","year":"2024","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0915","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0920","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","article-title":"Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease","volume":"16","author":"Arranz","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0925","first-page":"17","article-title":"Plasma p-tau217 in Alzheimer\u2019s disease: Lumipulse and ALZpath SIMOA head-to-head comparison","volume":"12","author":"Pilotto","year":"2024","journal-title":"Duilio Brugnoni"},{"key":"10.1016\/j.clinbiochem.2025.111015_b0930","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14140","article-title":"Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays","author":"Figdore","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111015_b0935","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1017\/S1041610209009405","article-title":"The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer\u2019s disease","volume":"21","author":"Ellis","year":"2009","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0940","doi-asserted-by":"crossref","unstructured":"A.E. Mammel, G.Y.R. Hsiung, A. Mousavi, et al., Title: Alzheimer\u2019s disease clinical decision points for two plasma p-tau217 laboratory developed tests in neuropathology confirmed samples, Abbreviated Title: Performance of two clinical plasma p-tau217 immoassays. https:\/\/doi.org\/10.1101\/2024.07.27.24310872.","DOI":"10.1101\/2024.07.27.24310872"},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111015_b0990","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111015_b0625","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA \u2013 J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0995","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41598-024-51334-x","article-title":"Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer\u2019s disease","volume":"14","author":"Kivis\u00e4kk","year":"2024","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111015_b0640","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P\u2010tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.111015_b0645","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b1000","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14536","article-title":"Plasma p\u2010tau217 and p\u2010tau217\/A\u03b21\u201042 are effective biomarkers for identifying CSF\u2010 and PET imaging\u2010diagnosed Alzheimer\u2019s disease: Insights for research and clinical practice","volume":"21","author":"Zhong","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.clinbiochem.2025.111015_b1005","doi-asserted-by":"crossref","unstructured":"A. Pilotto, V. Quaresima, C. Trasciatti et al., Plasma p-tau217 in Alzheimer\u2019s disease: Lumipulse and ALZpath SIMOA head-to-head comparison, Published online May 3, 2024. https:\/\/doi.org\/10.1101\/2024.05.02.24306780.","DOI":"10.1101\/2024.05.02.24306780"},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.111015_b1010","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1002\/alz.14140","article-title":"Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p\u2010tau217 immunoassays","volume":"20","author":"Figdore","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0945","series-title":"In","article-title":"Early detection and personalized medicine: future strategies against Alzheimer\u2019s disease","author":"Di Meco","year":"2021"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0950","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111015_b0955","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3233\/JAD-200884","article-title":"Views on early diagnosis of Alzheimer\u2019s disease among Dutch physicians: a qualitative interview study","volume":"79","author":"Tromp","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.111015_b0960","article-title":"An overview of new and emerging technologies for early diagnosis of Alzheimer disease: emerging health technologies","volume":"2","author":"Wells","year":"2022","journal-title":"Can. Agency Drugs Technol. Health"},{"key":"10.1016\/j.clinbiochem.2025.111015_b0965","unstructured":"Imaging Technology News, Isologic First diagnostic radiotracer for early diagnosis of Alzheimer\u2019s disease approved in Canada."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0970","unstructured":"https:\/\/www.impactad.org, IMPACT-AD."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111015_b0665","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0975","article-title":"Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population","volume":"121\u2013122","author":"Cooper","year":"2023","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2025.111015_b0980","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neurobiolaging.2023.06.018","article-title":"Modifiable risk factors for dementia, cognition, and plasma phosphorylated tau 181 in a large-scale cohort of Australian older adults","volume":"131","author":"Roccati","year":"2023","journal-title":"Neurobiol. Aging"},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111015_b0985","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/alz.12105","article-title":"Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia","volume":"16","author":"Ismail","year":"2020","journal-title":"Alzheimer\u2019s Dement."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:45:16Z","timestamp":1783158316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912025001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":159,"alternative-id":["S0009912025001444"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.111015","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The biological diagnosis of Alzheimer\u2019s disease using blood-based biomarkers: a Canadian prospective","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.111015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110980","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111015"}}